

Pharmacological targeting of age-related changes in skeletal muscle tissue

Aurel B. Leuchtmann and Christoph Handschin*

Biozentrum, University of Basel, Klingelbergstrasse 50/70, CH-4056 Basel, Switzerland

*Correspondence: christoph.handschin@unibas.ch

Published in Pharmacol Res. 2019 Mar 4. pii: S1043-6618(18)31953-4. PMID: 30844535. doi: 10.1016/j.phrs.2019.02.030.

Copyright © Elsevier; Pharmacological Research

Reprint request

Unfortunately, due to copyright-related issues, we are not able to post the post-print pdf version of our manuscript - in some cases, not even any version of our manuscript. Thus, if you would like to request a post-production, publisher pdf reprint, please click send an email with the request to christoph-dot-handschin_at_unibas-dot-ch (see <http://www.biozentrum.unibas.ch/handschin>).

Information about the Open Access policy of different publishers/journals can be found on the SHERPA/ROMEO webpage: <http://www.sherpa.ac.uk/romeo/>

Reprint Anfragen

Aufgrund fehlender Copyright-Rechte ist es leider nicht möglich, dieses Manuskript in der finalen Version, z.T. sogar in irgendeiner Form frei zugänglich zu machen. Anfragen für Reprints per Email an christoph-dot-handschin_at_unibas-dot-ch (s. <http://www.biozentrum.unibas.ch/handschin>).

Informationen zur Open Access Handhabung verschiedener Verlage/Journals sind auf der SHERPA/ROMEO Webpage verfügbar: <http://www.sherpa.ac.uk/romeo/>

Pharmacological targeting of age-related changes in skeletal muscle tissue

Aurel B. Leuchtmann and Christoph Handschin*

Biozentrum, University of Basel, Klingelbergstrasse 50/70, CH-4056 Basel, Switzerland

*Correspondence: christoph.handschin@unibas.ch

Abstract

Sarcopenia, the age-related loss of skeletal muscle mass and function, increases the risk of developing chronic diseases in older individuals and is a strong predictor of disability and death. Because of the ongoing demographic transition, age-related muscle weakness is responsible for an alarming and increasing contribution to health care costs in Western countries. Exercise-based interventions are most successful in preventing the decline in skeletal muscle mass and in preserving or ameliorating functional capacities with increasing age. However, other treatment options are still scarce. In this review, we explore currently applied nutritional and pharmacological approaches to mitigate age-related muscle wasting, and discuss potential future therapeutic avenues.

Introduction

Sarcopenia is a geriatric syndrome characterized by the loss of skeletal muscle mass and function that develops gradually during aging [1]. Data from cross-sectional studies indicate that muscle mass and strength reach their peak values between the second and the fourth decade of life and start to decline continuously from between the third and fifth decade [1]. Besides neurodegenerative events and mental decline, sarcopenia is the main cause for loss-of-independence, the inability to perform daily tasks and social interactions, frailty and falls, admission to nursing homes, and thus reduced overall quality of life, morbidity and mortality. Muscle aging involves complex qualitative and quantitative changes in the neuromuscular system [2]. However, the etiology of sarcopenia is still poorly understood and it is unknown to what extent the development is an inevitable consequence of aging and/or the result of a combination of additional factors including a decrease in physical activity, nutrient deficiencies and genetic predisposition. Age-related co-morbidities such as cardiovascular diseases, obesity and type 2 diabetes, the decline of hormones [e.g. estrogens, androgens and growth hormone (GH)] as well as age-associated chronic, systemic low-grade inflammation likely also contribute to the development of sarcopenia and may account for inter-individual variations in the age of onset and slope of progression.

Due to the demographic transition, the world's geriatric population is continuously expanding, resulting in an ever-increasing number of sarcopenic patients, tightly linked to enormous personal, social and financial burdens. To date, exercise and an active life-style are the most effective interventions for preventing the decline in skeletal muscle mass and preserving or even ameliorating functional capacities with increasing age. In fact, a recent systematic meta-analysis of muscle morphology and performance in master athletes suggests that exercise training preserves physical function, muscular strength and body fat levels with increasing age similar to that of young, healthy individuals [3]. However, to overcome issues with compliance, adherence, and, in the case of co-morbidities, exercise intolerance, other approaches would be of high clinical relevance. Unfortunately, efficient pharmacological avenues are still lacking. In this review, we discuss applied and emerging nutritional and pharmacological strategies for the treatment and prevention of sarcopenia with regard to benefits, limitations and open questions.

Age-associated anabolic resistance

In general, skeletal muscle mass is determined by the balance between muscle protein synthesis (MPS) and muscle protein breakdown (MPB) controlled by an overarching process called proteostasis. Thus, loss of muscle mass often is the result of a negative net protein balance arising from a reduction in MPS and/or increase in MPB. Dietary protein and exercise are two independent stimuli for MPS and act synergistically leading to a net increase of skeletal muscle mass when combined [4]. Aging is

associated with an attenuated response of MPS to both, protein ingestion [5] and exercise [6], a phenomenon known as anabolic resistance. Thus, analogous to the impaired sensitivity to insulin in insulin-resistant patients (e.g. in type 2 diabetes), skeletal muscle becomes less sensitive to essential amino acids and/or training stimuli. A decline in muscular activity, chronic, systemic low-grade inflammation (including that of skeletal muscle) as well as impaired digestion and/or absorption of dietary protein are hypothesized to contribute to this reduced sensitivity. Therefore, exercise, anti-inflammatory interventions and specific dietary modifications may help to overcome age-related anabolic resistance.

Nutritional Strategies

For a variety of reasons, under- and malnutrition are often observed in elderly individuals, leading to inadequate caloric and/or deficient macro- and micronutrient intake [7, 8]. Accordingly, dietary interventions are of high interest to mitigate sarcopenia, even though only limited and inconsistent evidence exists, primarily based on cross-sectional studies [9]. Nevertheless, several micro- and macronutrients, including protein, essential amino acids, omega-3 (n-3) polyunsaturated fatty acids (PUFAs) as well as caloric restriction (CR) as dietary intervention have been suggested to exert beneficial effects on sarcopenia and therefore, are discussed in the following sections.

Protein and amino acids

Besides exercise, protein intake provides the main anabolic stimulus to skeletal muscle. Upon protein ingestion, amino acid levels rise in the blood (hyperaminoacidemia), stimulate MPS and suppress MPB. Basal (i.e. unstimulated) levels of MPS and MPB often do not change with increasing age [10, 11]. In contrast, there is emerging evidence that older individuals show a compromised stimulation of MPS (and maybe also a reduced inhibition of MPB) in response to protein ingestion [5], which may be further exacerbated by physical inactivity and short periods of bedrest [12]. However, this blunted response to dietary protein can partially be overcome with higher amounts of protein per single meal [5]. In particular, protein quality i.e. the content of the amino acid leucine appears to be crucial [13, 14]. Of all amino acids, leucine and its metabolite β -hydroxy- β -methylbutyrate (HMB) [15] have the most potent ability to activate the mammalian target of rapamycin complex 1 (mTORC1), which subsequently phosphorylates the downstream signaling targets ribosomal protein S6 kinase 1 (S6K1) and eukaryotic translation initiation factor 4E-binding protein 1 (4E-BP1) that facilitate translation initiation and stimulation of MPS (Figure 1) [16]. The effect of leucine can further be potentiated by co-ingestion of other branched-chain amino acids or the whole spectrum of essential amino acids [17]. Of note, Katsanos et al. [14] observed that the leucine content in a mixture of essential amino acids needed to be higher in older compared to younger men (1.7 g vs. 2.8 g) to stimulate MPS. Therefore,

it has been proposed that older individuals may benefit not only from eating higher amounts of protein, but also from using high quality (i.e. leucine rich) sources and optimally, evenly distribute the intake throughout the day to robustly stimulate MPS in a sustained manner [18]. However, 6% of men and 12% of women aged 70 years or above do not meet the United States' Estimated Average Requirement (EAR) and Recommended Dietary Allowance (RDA) for protein [18]. Moreover, since the current EAR and RDA for protein intake in elderly adults might be too low [18], the number of people getting insufficient amounts of protein may be underestimated. Nevertheless, the general recommendation of a higher protein intake for elderly adults as an antisarcopenic stimulus is still debated. Recent observational studies indicate that higher protein intake is associated with better preservation of muscle mass and function with aging [18] and results from short-term intervention studies suggest that improving dietary protein quality and quantity may partially reduce the negative effects of short-term physical inactivity on muscle mass [19, 20] and function [19-21]. On the other hand, clinical trials so far have failed to demonstrate the effectiveness of protein supplementation to promote muscle mass and function in elderly adults [22-24] and only a few long-term longitudinal trials assessing the potential protective effect of higher protein intake on muscle mass and function with aging exist [25]. Furthermore, results on the enhancing effect of protein supplementation on resistance training-mediated improvements in muscle mass and strength of older adults have been conflicting [26]. Thus, more long-term intervention trials will have to demonstrate the efficacy of protein intake at different levels and qualities to mediate benefits to the aging population.

Omega-3 polyunsaturated fatty acids

N-3 PUFAs modulate the biophysical properties of cell membranes and are involved in lipid signaling processes. The n-3 PUFAs eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) exhibit anti-inflammatory properties [27] and are frequently consumed as fish oil supplements. Besides potential effects on chronic, systemic inflammation, n-3 PUFAs may also sensitize skeletal muscle to the anabolic stimuli of resistance exercise and dietary amino acids [28]. In an 8-week supplementation trial, n-3 PUFAs potentiated MPS and increased mTORC1-p70S6K1 phosphorylation in response to a hyperaminoacidemic-hyperinsulinemic clamp in older adults [28]. Sedentary elderly men and women (60-85 years old) participating in a randomized controlled trial of 6-month fish oil-derived n-3 PUFA supplementation further functionally benefited from improved average isokinetic power, thigh muscle volume, handgrip strength, and one-repetition maximum [29]. However, despite these positive reports, the exact effects of n-3 PUFA supplementation on skeletal muscle of older individuals remain to be determined. In particular, the time course of EPA and DHA integration in muscle cell walls, as well as the exact dosing have to be evaluated [30]. For example, 3 months of daily supplementation with 1.3 g of n-3 PUFAs was not affecting muscle strength and physical function [31], whereas a similar

6-month treatment was sufficient [29]. Moreover, in a recent trial, a combination of 3 g daily fish oil with exercise training for 3 months enhanced exercise-induced gains in isometric torque and muscle quality (strength per unit muscle area) in female participants but, curiously, not in males [32].

In summary, there is increasing evidence that n-3 PUFAs can act as anabolic enhancers on skeletal muscle of elderly people. The effects of n-3 PUFAs have mainly been attributed to their anti-inflammatory properties, but the fact that n-3 PUFA supplementation regimens seem to have similar anabolic effects also in younger adults [33, 34] may indicate the presence of a more direct effect on skeletal muscle. Thus, further studies are required to elucidate the underlying mechanisms and to prove the efficacy of fish oil supplementation as sarcopenia treatment.

Caloric restriction

CR increases lifespan in several species ranging from yeast to mammals and potentially even primates [35]. CR dampens mTORC1 activity [36] based on the reduced abundance of nutrients and insulin, as well as from the activation of the potent mTORC1 inhibitor AMP-dependent protein kinase (AMPK). Metformin, a putative AMPK activator, is currently being tested for sarcopenia [37]. In general though, CR as an anti-sarcopenic intervention seems counterintuitive, since activation of mTORC1 is linked to increased MPS and hypertrophy. However, mTORC1 activity might be pathologically elevated in old muscle, at least in mice [38] and one human cohort [11]. As chronic activation of mTORC1 signaling has been associated with muscle wasting [39], sarcopenic elderly could thus benefit from CR interventions aimed at inhibiting mTORC1 activity. Importantly however, inhibiting mTORC1 signaling with rapamycin also blocks essential amino acid induced stimulation of MPS [40], prevents or blunts the increase of MPS and/or muscle mass following resistance exercise in both rodents [41] and humans [42], but not basal, post-absorptive protein metabolism [43]. The use of dietary or pharmacological means to inhibit mTORC1 activity in old muscle thus remains to be explored. CR however elicits other, non-mTORC1-related potential benefits for sarcopenic patients, e.g. the ability to reduce chronic, systemic low-grade inflammation, as demonstrated in an aging rat model [44]. Furthermore, CR-mediated stimulation of mitochondrial function and oxidative metabolism could contribute to therapeutic effects [45], potentially mediated by sirtuins and the peroxisome proliferator activated receptor γ coactivator 1 α (PGC-1 α) [46]. Finally, the CR-associated reduction in obesity and other co-morbidities such as cardiovascular pathologies and type 2 diabetes could further alleviate the health of elderly individuals.

Anti-inflammatory drugs

A persistent, systemic low-grade inflammation is highly associated with a number of chronic diseases [47, 48]. In skeletal muscle, inflammatory cytokines activate molecular pathways involved in muscle

mass regulation, leading to an imbalance in anabolic and catabolic processes [49]. Aging has also been associated with increased levels of circulating pro-inflammatory markers [50, 51], which negatively correlated with muscle mass and strength in elderly adults [52]. In fact, this state of chronic, systemic low-grade inflammation has been termed “inflammaging” [53]. Non-steroidal anti-inflammatory drugs (NSAIDs) reduce systemic low-grade inflammation at least in part by inhibiting cyclooxygenases (COX-1 and COX-2), the key enzymes of leukotriene and prostaglandin synthesis, mediators of inflammation and pain. Long-term treatment of aged rats with the non-selective COX inhibitor ibuprofen improved inflammatory markers, preserved the anabolic response to food intake and increased muscle mass [54]. Notably however, concomitant administration of ibuprofen with exercise in young rodents impaired skeletal muscle regeneration [55], whereas the potent COX-1-selective NSAID indomethacin boosted inflammatory processes in skeletal muscle and brain [56]. Similarly, high doses of NSAIDs compromise muscle strength and hypertrophic adaptations to resistance exercise in young individuals [57]. In contrast, resistance training combined with daily ibuprofen consumption did either not affect [58, 59] or even increased muscle mass [60] and strength [61] in elderly populations. These findings indicate that the usage of NSAIDs in sarcopenia remains to be explored, but may potentially be relevant in later stages of sarcopenia or in conditions with inflammatory comorbidities [63].

Inhibitors of the renin-angiotensin-aldosterone system

The renin-angiotensin-aldosterone (RAA) regulatory circuit controls blood pressure and electrolyte balance. The enzyme renin converts angiotensinogen to angiotensin I, which in turn is cleaved by the angiotensin-converting enzyme (ACE) to the active hormone angiotensin II. The effects of RAA activity on skeletal muscle are significant, but yet still poorly understood. For example, reduced expression of ACE has been associated with a greater anabolic response to training [64]. Inversely, infusion of angiotensin II increases proteolysis and decreases local and systemic insulin-like growth factor 1 (IGF-1) levels [65]. Muscle-specific IGF-1 expression prevents angiotensin II-induced skeletal muscle wasting [66]. Besides their potent effects on cardiovascular and endothelial function, inhibitors of the RAA system could have anti-inflammatory effects by decreasing angiotensin II-induced NF- κ B (nuclear factor κ B) activation, thereby blocking the production of interleukin 6 (IL-6) and C-reactive protein (CRP) [63]. This effect might complement the improvements in cardiac output, hemodynamic parameters and endothelial function that positively affect muscle metabolism and function [67]. For example, in a cohort of 641 aging women with hypertension, the use of ACE inhibitors was associated with a lower decline in muscle strength and walking speed over a three-year period [68]. The ACE inhibitor perindopril improved six-minute walking distance in a double-blind randomized controlled trial with 130 geriatric patients [69]. In contrast, the ACE inhibitor fosinopril had no significant effect on the inflammatory profile (CRP, IL-6 and PAI-1 levels) [70] or physical performance [71] of adults with

elevated cardiovascular risk. Discrepancies in the outcome might be explained by differences in inflammatory profiles of the participants at baseline [63]. In old mice, the angiotensin receptor type 1 (AT1R) inhibitor losartan prevented immobilization-induced muscle loss [72], improved measures of physical function and decreased IL-6 levels [73]. Whether losartan has similar effects in humans is currently investigated in a clinical trial with older adults [49].

Myostatin pathway and activin type II receptor function

Myostatin and its downstream signaling pathways are strong negative regulators of muscle mass. It is unclear whether myostatin and related factors, e.g. GDF11, contribute to the disease etiology of sarcopenia [74, 75]. Blocking myostatin signaling might nevertheless be a promising strategy to increase muscle mass in many wasting contexts, including sarcopenia [49]. In old mice, myostatin knockout results in muscle fiber hypertrophy, increased activation of satellite cells *in vitro* and improvements of muscle regeneration [76, 77]. Disappointingly though, neutralization of the myostatin protein with humanized myostatin antibodies (LY2495655 and REGN1033) only slightly increased appendicular lean body mass and gait speed in sarcopenic elderly, and did not ameliorate grip strength despite the achieved gains in muscle mass [78, 79]. Since the myostatin receptor complex (activin type IIB receptor and activin receptor-like kinase 4 or 5) is activated by multiple ligands, blockage of receptor function might be a more promising approach [80]. Different strategies to reduce activity of this receptor are currently being pursued and clinical trials with myostatin pathway inhibitors are in progress, including in sarcopenic patients [49].

Testosterone and selective androgen receptor modulators

Cross-sectional and longitudinal studies in aging men indicate that testosterone levels gradually decrease between the third and the ninth decade of life, with high inter-individual variability [81-84]. This aging-associated reduction in androgen production and/or bioavailability is thought to contribute to muscular atrophy and the development of sarcopenia. Testosterone treatment stimulates muscle protein synthesis and induces muscle fiber hypertrophy in a dose-dependent manner [85] and, therefore, testosterone replacement therapy has been used as treatment strategy for sarcopenia. For example, in hypogonadal pre-frail and frail elderly men, daily dermal testosterone gel application for six months increased serum testosterone levels and preserved muscle thickness [86]. Testosterone also improves muscle strength in women [87]. Even though the effects of testosterone on the balance between MPS and MPB are thought to be predominately mediated by its binding to the androgen receptor (AR) thereby inducing IGF-I transcription and/or interacting with phosphoinositide 3-kinase (PI3K) to activate the PI3K-Akt/protein kinase B (PKB)-mTORC1 pathway, the exact mechanism of testosterone action in skeletal muscle has not been fully elucidated so far [88]. Moreover, despite

promising effects on muscle mass [89] and in some cases also force [90], improved muscle function was not achieved in all trials. Importantly, due to the high number of serious adverse effects (e.g. increased risk of prostate cancer and cardiovascular events, erythrocytosis, behavioral abnormalities, and virilization in women) [91-93], androgen replacement therapies are non-viable treatment options for general prescription if applied in a non-substituting manner. To circumvent the problem of adverse effects that are mostly linked to androgenic and/or non-skeletal muscle tissue-linked effects of androgens, selective androgen receptor modulators (SARMs) that retain anabolic, but lose androgenic properties might be a safer treatment option, even if skeletal muscle-specificity cannot be achieved. For example, the SARM enbosarm elicits a dose-dependent increase in total lean body mass as well as improvements in physical function in both older male and female participants, importantly without an increased risk of adverse effects [94]. Treatment with MK-0773, another SARM, increased lean body mass of sarcopenic elderly women but had no effect on muscle strength [95]. There was no evidence for androgenization induced by MK-0773, but several participants in the treatment group showed elevated transaminase levels. Different SARMS are currently being evaluated in clinical trials [49].

Growth hormone and insulin-like growth factor 1

GH is synthesized in the adenohypophysis and affects skeletal muscle indirectly by stimulating IGF-1 release by the liver, which in turn acts on skeletal muscle via the IGF-1-receptor (IGF-1R) and subsequent activation of the PI3K-Akt/PKB-mTORC1 pathway [96]. Accordingly, in mice with a skeletal muscle-specific ablation of the IGF-1R, GH administration does not increase muscle mass [97]. In humans, aging is associated with a decrease in GH secretion and lower levels of circulating IGF-1 [98]. In line, GH replacement therapy increases lean mass in older men with a relative GH-deficiency [99] and daily injection of recombinant GH prevented a decline in muscle cross-sectional area (CSA) during two weeks of single leg immobilization and led to a greater increase of muscle CSA during the following six weeks of rehabilitation training compared to a placebo treated group [100]. Similarly, various forms of human recombinant IGF-1 are being assessed for their therapeutic value in sarcopenia and other muscle wasting diseases [101, 102]. However, while GH and IGF-1 treatment may be beneficial in individuals with relative deficiencies, non-replacement therapy of both hormones might be hampered by severe adverse effects, including cardiovascular complications and glucose intolerance [103].

Vitamin D

The synthesis of the active form of the hormone vitamin D requires skin exposure to sunlight (*i.e.* UVB light) [104]. Accordingly, older adults are at higher risk of vitamin D deficiency due to limited sun exposure, decreased capacity for cutaneous vitamin D synthesis and reduced intake and/or absorbance of vitamin D from the diet [105]. Even though the main function of vitamin D entails the

regulation of calcium homeostasis and bone metabolism, skeletal muscle tissue also expresses the vitamin D receptor (VDR) [106] and knockout of the VDR results in muscular abnormalities [107]. Moreover, an increasing body of literature suggests a relationship between serum 25-hydroxyvitamin D [25(OH)D] levels and skeletal muscle physiology in elderly adults. Vitamin D deficiency is associated with reduced muscle mass and function, whereas vitamin D treatment seems to improve these parameters [108, 109]. Moreover, VDR expression has been reported to decrease in muscle with age [110] and VDR gene polymorphisms may further modify the risk of sarcopenia, even though the exact contribution of different genotypes has yet to be identified [111].

Given the blunted responsiveness of elderly adults to dietary protein and resistance exercise that often correlates with low levels of vitamin D, it has been suggested that vitamin D supplementation may overcome anabolic resistance. For example, participants with higher 25(OH)D levels and higher dietary protein intake at baseline responded with greater gains in muscle mass to a vitamin D- and leucine-enriched whey protein diet for 13 weeks [112]. Furthermore, a one year vitamin D supplementation together with a HMB-, arginine- and lysine-containing drink resulted in increased fat-free mass in elderly adults without exercise training, but only in those individuals with a 25(OH)D status of ≥ 30 nmol/ml [113]. Similarly, vitamin D supplementation significantly increased muscle strength in older adults [114] and treating women with low vitamin D levels resulted in 10% increase in muscle fiber size [115]. In fact, resistance exercise and vitamin D supplementation provide reciprocally beneficial effects on strength gains [116] and bone mineral density compared to exercise or vitamin D supplementation alone [116]. Despite these observations, the underlying mechanisms of vitamin D action in skeletal muscle remain enigmatic. Moreover, while the effects of vitamin D supplementation may be more pronounced in individuals with lower levels [109, 117], the optimal dose, route of administration, dosing intervals and treatment duration require further investigations [118]. Finally, a recent analysis showed no benefit of vitamin D supplementation on clinically relevant outcome measures such as fractures, falls or bone mineral density [119].

Ghrelin

The gastrointestinal peptide hormone ghrelin has originally been discovered as an endogenous ligand for the growth hormone secretagogue receptor 1a that has the ability to stimulate GH release [120]. Subsequent studies revealed a broad spectrum of additional physiological functions of ghrelin, including the regulation of feeding behavior by stimulating appetite and food intake as well as the promotion of anti-inflammatory processes [121]. Ghrelin treatment has accordingly been suggested to counteract muscle wasting in sarcopenia in several different ways. First, given that elderly people often lose appetite, ghrelin may increase food intake, helping these individuals to meet adequate energy and nutrient goals to maintain their muscle mass. Accordingly, in studies on cancer patients suffering

from cachexia, synthetic ghrelin receptor agonists increased food intake and muscle mass [49]. However, other functional parameters, such as grip strength, could not be ameliorated by ghrelin treatment. Second, ghrelin-stimulated GH release and the subsequent increase of hepatic IGF-1 production might help to enhance or restore IGF-1 signaling in sarcopenic elderly. Capromorelin, a ghrelin receptor agonist, elevated GH and IGF-1 levels and improved lean mass, tandem walk and stair climbing after one year of treatment in older adults with mild functional limitations [122]. In a one-year randomized double-blind placebo-controlled crossover trial with healthy elderly adults, the ghrelin receptor agonist ibutamoren (MK-677) restored GH and IGF-1 to levels observed in young adults [123]. However, reliable functional endpoints could not be assessed due to the short duration and low sample size of the study. In a later trial, MK-677 was given to people recovering from a hip fracture for a period of 24 weeks. Participants showed higher IGF-1 levels and mild improvements in stair climbing and gait speed but unfortunately, the trial had to be stopped early because of adverse effects [124]. Third, numerous animal studies suggest anti-inflammatory properties of ghrelin and ghrelin receptor agonists [121]. However, human trials demonstrating reduced inflammation with ghrelin treatment have yet to be conducted. Taken together, even though ghrelin may exert beneficial effects on sarcopenia by restoring food intake and increasing muscle mass, the applicability is limited as effects on functional endpoints are modest and clinical trials with long-term follow-ups to evaluate the risk of adverse effects are lacking.

Conclusions and future perspectives

To date, pharmacological therapies for sarcopenia remain elusive, either because clinical trials revealed little efficacy or unacceptable adverse effects. However, treatment options for muscle wasting disorders have expanded dramatically in recent years and a number of new compounds and approaches are currently being evaluated in patients [49]. Several of these are of potential interest for the prevention and treatment of sarcopenia, at least if certain limitations can be overcome. For example, besides the ongoing debate whether aging represents a disease or a natural, physiological process [125], the design of clinical trials for sarcopenia is not trivial: age of participants, length of the trial or the definition of soft and hard endpoints are only some of the open questions that have to be addressed. Nevertheless, besides the phase II and III compounds, other pharmacological and nutritional agents are currently in the experimental stage, and might enter clinical testing in the future, potentially expanding the repertoire of drugs for muscle wasting and sarcopenia [45, 49, 126]. Finally, multi-pronged approaches using combinations of pharmacological and nutritional interventions might result in a positive outcome for sarcopenia. Until then, exercise remains the primary and most efficient intervention to prevent and mitigate sarcopenia, in particular when combined with adequate dietary approaches and skin exposure to sunlight. Of note, while resistance exercise confers the main benefits

350 on muscle mass and strength, endurance training can further help to increase muscular sensitivity to
351 anabolic stimuli and by promoting tissue vascularization, cardiovascular and metabolic benefits.
352 Accordingly, a combination of both types of exercise most likely contributes most to an optimized
353 health span [48, 127, 128]. It thus should be the interest of all stake-holders, including patients,
354 insurance companies and governments, to implement broad incentives for an active life-style to
355 overcome the problems with adherence and compliance.
356

Conflict of interest: The authors have no conflict of interest related to this manuscript.

Acknowledgments: We thank Prof. Urs T. Rüegg for discussions on the manuscript. Work in our laboratory is funded by the Swiss National Science Foundation, the European Research Council (ERC) Consolidator grant 616830-MUSCLE_NET, Swiss Cancer Research grant KFS-3733-08-2015, the Swiss Society for Research on Muscle Diseases (SSEM), SystemsX.ch, the Novartis Stiftung für Medizinisch-Biologische Forschung and the University of Basel.

366 **References**

- 367 [1] A.J. Cruz-Jentoft, G. Bahat, J. Bauer, Y. Boirie, O. Bruyere, T. Cederholm, C. Cooper, F. Landi, Y.
368 Rolland, A.A. Sayer, S.M. Schneider, C.C. Sieber, E. Topinkova, M. Vandewoude, M. Visser, M.
369 Zamboni, Writing Group for the European Working Group on Sarcopenia in Older People (EWGSOP2),
370 and the Extended Group for EWGSOP2, Sarcopenia: revised European consensus on definition and
371 diagnosis, *Age Ageing* (2018).
- 372 [2] L. Larsson, H. Degens, M. Li, L. Salviati, Y.I. Lee, W. Thompson, J.L. Kirkland, M. Sandri, Sarcopenia:
373 Aging-Related Loss of Muscle Mass and Function, *Physiol Rev* 99(1) (2019) 427-511.
- 374 [3] J. McKendry, L. Breen, B.J. Shad, C.A. Greig, Muscle morphology and performance in master
375 athletes: A systematic review and meta-analyses, *Ageing Res Rev* 45 (2018) 62-82.
- 376 [4] N.M. Cermak, P.T. Res, L.C. de Groot, W.H. Saris, L.J. van Loon, Protein supplementation
377 augments the adaptive response of skeletal muscle to resistance-type exercise training: a meta-
378 analysis, *Am J Clin Nutr* 96(6) (2012) 1454-64.
- 379 [5] D.R. Moore, T.A. Churchward-Venne, O. Witard, L. Breen, N.A. Burd, K.D. Tipton, S.M. Phillips,
380 Protein ingestion to stimulate myofibrillar protein synthesis requires greater relative protein intakes
381 in healthy older versus younger men, *J Gerontol A Biol Sci Med Sci* 70(1) (2015) 57-62.
- 382 [6] V. Kumar, A. Selby, D. Rankin, R. Patel, P. Atherton, W. Hildebrandt, J. Williams, K. Smith, O.
383 Seynnes, N. Hiscock, M.J. Rennie, Age-related differences in the dose-response relationship of muscle
384 protein synthesis to resistance exercise in young and old men, *J Physiol* 587(1) (2009) 211-7.
- 385 [7] I. Artaza-Artabe, P. Saez-Lopez, N. Sanchez-Hernandez, N. Fernandez-Gutierrez, V. Malafarina,
386 The relationship between nutrition and frailty: Effects of protein intake, nutritional supplementation,
387 vitamin D and exercise on muscle metabolism in the elderly. A systematic review, *Maturitas* 93
388 (2016) 89-99.
- 389 [8] M.K. Esquivel, Nutritional Assessment and Intervention to Prevent and Treat Malnutrition for Fall
390 Risk Reduction in Elderly Populations, *Am J Lifestyle Med* 12(2) (2018) 107-112.
- 391 [9] I. Bloom, C. Shand, C. Cooper, S. Robinson, J. Baird, Diet Quality and Sarcopenia in Older Adults: A
392 Systematic Review, *Nutrients* 10(3) (2018).
- 393 [10] E. Volpi, M. Sheffield-Moore, B.B. Rasmussen, R.R. Wolfe, Basal muscle amino acid kinetics and
394 protein synthesis in healthy young and older men, *JAMA* 286(10) (2001) 1206-12.
- 395 [11] M.M. Markofski, J.M. Dickinson, M.J. Drummond, C.S. Fry, S. Fujita, D.M. Gundermann, E.L.
396 Glynn, K. Jennings, D. Paddon-Jones, P.T. Reidy, M. Sheffield-Moore, K.L. Timmerman, B.B.
397 Rasmussen, E. Volpi, Effect of age on basal muscle protein synthesis and mTORC1 signaling in a large
398 cohort of young and older men and women, *Exp Gerontol* 65 (2015) 1-7.
- 399 [12] R.E. Tanner, L.B. Brunker, J. Agergaard, K.M. Barrows, R.A. Briggs, O.S. Kwon, L.M. Young, P.N.
400 Hopkins, E. Volpi, R.L. Marcus, P.C. LaStayo, M.J. Drummond, Age-related differences in lean mass,
401 protein synthesis and skeletal muscle markers of proteolysis after bed rest and exercise
402 rehabilitation, *J Physiol* 593(18) (2015) 4259-73.
- 403 [13] J.C. Anthony, F. Yoshizawa, T.G. Anthony, T.C. Vary, L.S. Jefferson, S.R. Kimball, Leucine
404 stimulates translation initiation in skeletal muscle of postabsorptive rats via a rapamycin-sensitive
405 pathway, *J Nutr* 130(10) (2000) 2413-9.
- 406 [14] C.S. Katsanos, H. Kobayashi, M. Sheffield-Moore, A. Aarsland, R.R. Wolfe, A high proportion of
407 leucine is required for optimal stimulation of the rate of muscle protein synthesis by essential amino
408 acids in the elderly, *Am J Physiol Endocrinol Metab* 291(2) (2006) E381-7.
- 409 [15] J.S. Jakubowski, E.P.T. Wong, E.A. Nunes, K.S. Noguchi, J.K. Vandeweerd, K.T. Murphy, R.W.
410 Morton, C. McGlory, S.M. Phillips, Equivalent Hypertrophy and Strength Gains in HMB- or Leucine-
411 supplemented Men, *Med Sci Sports Exerc* (2018).
- 412 [16] Y. Sancak, L. Bar-Peled, R. Zoncu, A.L. Markhard, S. Nada, D.M. Sabatini, Ragulator-Rag complex
413 targets mTORC1 to the lysosomal surface and is necessary for its activation by amino acids, *Cell*
414 141(2) (2010) 290-303.
- 415 [17] M. Moberg, W. Apro, B. Ekblom, G. van Hall, H.C. Holmberg, E. Blomstrand, Activation of
416 mTORC1 by leucine is potentiated by branched-chain amino acids and even more so by essential
417 amino acids following resistance exercise, *Am J Physiol Cell Physiol* 310(11) (2016) C874-84.

- [18] D.A. Traylor, S.H.M. Gorissen, S.M. Phillips, Perspective: Protein Requirements and Optimal Intakes in Aging: Are We Ready to Recommend More Than the Recommended Daily Allowance?, *Adv Nutr* 9(3) (2018) 171-182.
- [19] D. Paddon-Jones, M. Sheffield-Moore, R.J. Urban, A.P. Sanford, A. Aarsland, R.R. Wolfe, A.A. Ferrando, Essential amino acid and carbohydrate supplementation ameliorates muscle protein loss in humans during 28 days bedrest, *J Clin Endocrinol Metab* 89(9) (2004) 4351-8.
- [20] E.J. Arentson-Lantz, E. Galvan, J. Ellison, A. Wacher, D. Paddon-Jones, Improving Dietary Protein Quality Reduces the Negative Effects of Physical Inactivity on Body Composition and Muscle Function, *J Gerontol A Biol Sci Med Sci* (2019).
- [21] K.L. English, J.A. Mettler, J.B. Ellison, M.M. Mamerow, E. Arentson-Lantz, J.M. Patarini, R. Ploutz-Snyder, M. Sheffield-Moore, D. Paddon-Jones, Leucine partially protects muscle mass and function during bed rest in middle-aged adults, *Am J Clin Nutr* 103(2) (2016) 465-73.
- [22] Z.R. Xu, Z.J. Tan, Q. Zhang, Q.F. Gui, Y.M. Yang, Clinical effectiveness of protein and amino acid supplementation on building muscle mass in elderly people: a meta-analysis, *PLoS One* 9(9) (2014) e109141.
- [23] M. Tieland, R. Franssen, C. Dullemeijer, C. van Dronkelaar, H. Kyung Kim, T. Ispoglou, K. Zhu, R.L. Prince, L.J.C. van Loon, L. de Groot, The Impact of Dietary Protein or Amino Acid Supplementation on Muscle Mass and Strength in Elderly People: Individual Participant Data and Meta-Analysis of RCT's, *J Nutr Health Aging* 21(9) (2017) 994-1001.
- [24] S. Bhasin, C.M. Apovian, T.G. Travison, K. Pencina, L.L. Moore, G. Huang, W.W. Campbell, Z. Li, A.S. Howland, R. Chen, P.E. Knapp, M.R. Singer, M. Shah, K. Secinaro, R.V. Eder, K. Hally, H. Schram, R. Bearup, Y.M. Beleva, A.C. McCarthy, E. Woodbury, J. McKinnon, G. Fleck, T.W. Storer, S. Basaria, Effect of Protein Intake on Lean Body Mass in Functionally Limited Older Men: A Randomized Clinical Trial, *JAMA Intern Med* 178(4) (2018) 530-541.
- [25] C.K. McDonald, M.Z. Ankarfeldt, S. Capra, J. Bauer, K. Raymond, B.L. Heitmann, Lean body mass change over 6 years is associated with dietary leucine intake in an older Danish population, *Br J Nutr* 115(9) (2016) 1556-62.
- [26] R.W. Morton, K.T. Murphy, S.R. McKellar, B.J. Schoenfeld, M. Henselmans, E. Helms, A.A. Aragon, M.C. Devries, L. Banfield, J.W. Krieger, S.M. Phillips, A systematic review, meta-analysis and meta-regression of the effect of protein supplementation on resistance training-induced gains in muscle mass and strength in healthy adults, *Br J Sports Med* 52(6) (2018) 376-384.
- [27] P.C. Calder, n-3 polyunsaturated fatty acids, inflammation, and inflammatory diseases, *Am J Clin Nutr* 83(6 Suppl) (2006) 1505S-1519S.
- [28] G.I. Smith, P. Atherton, D.N. Reeds, B.S. Mohammed, D. Rankin, M.J. Rennie, B. Mittendorfer, Dietary omega-3 fatty acid supplementation increases the rate of muscle protein synthesis in older adults: a randomized controlled trial, *Am J Clin Nutr* 93(2) (2011) 402-12.
- [29] G.I. Smith, S. Julliard, D.N. Reeds, D.R. Sinacore, S. Klein, B. Mittendorfer, Fish oil-derived n-3 PUFA therapy increases muscle mass and function in healthy older adults, *Am J Clin Nutr* 102(1) (2015) 115-22.
- [30] S.M. Phillips, Nutritional supplements in support of resistance exercise to counter age-related sarcopenia, *Adv Nutr* 6(4) (2015) 452-60.
- [31] R. Krzyminska-Siemaszko, N. Czepulis, M. Lewandowicz, E. Zasadzka, A. Suwalska, J. Witowski, K. Wieczorowska-Tobis, The Effect of a 12-Week Omega-3 Supplementation on Body Composition, Muscle Strength and Physical Performance in Elderly Individuals with Decreased Muscle Mass, *Int J Environ Res Public Health* 12(9) (2015) 10558-74.
- [32] M. Da Boit, R. Sibson, S. Sivasubramaniam, J.R. Meakin, C.A. Greig, R.M. Aspden, F. Thies, S. Jeromson, D.L. Hamilton, J.R. Speakman, C. Hambly, A.A. Mangoni, T. Preston, S.R. Gray, Sex differences in the effect of fish-oil supplementation on the adaptive response to resistance exercise training in older people: a randomized controlled trial, *Am J Clin Nutr* 105(1) (2017) 151-158.
- [33] G.I. Smith, P. Atherton, D.N. Reeds, B.S. Mohammed, D. Rankin, M.J. Rennie, B. Mittendorfer, Omega-3 polyunsaturated fatty acids augment the muscle protein anabolic response to hyperinsulinaemia-hyperaminoacidaemia in healthy young and middle-aged men and women, *Clin Sci (Lond)* 121(6) (2011) 267-78.

- [34] C. McGlory, S.H.M. Gorissen, M. Kamal, R. Bahniwal, A.J. Hector, S.K. Baker, A. Chabowski, S.M. Phillips, Omega-3 fatty acid supplementation attenuates skeletal muscle disuse atrophy during two weeks of unilateral leg immobilization in healthy young women, *FASEB J* (2019) fj201801857RRR.
- [35] S.H. Lee, K.J. Min, Caloric restriction and its mimetics, *BMB Rep* 46(4) (2013) 181-7.
- [36] M. Shimobayashi, M.N. Hall, Making new contacts: the mTOR network in metabolism and signalling crosstalk, *Nat Rev Mol Cell Biol* 15(3) (2014) 155-62.
- [37] D.E. Long, B.D. Peck, J.L. Martz, S.C. Tuggle, H.M. Bush, G. McGwin, P.A. Kern, M.M. Bamman, C.A. Peterson, Metformin to Augment Strength Training Effective Response in Seniors (MASTERS): study protocol for a randomized controlled trial, *Trials* 18(1) (2017) 192.
- [38] Z. White, R.B. White, C. McMahon, M.D. Grounds, T. Shavlakadze, High mTORC1 signaling is maintained, while protein degradation pathways are perturbed in old murine skeletal muscles in the fasted state, *Int J Biochem Cell Biol* 78 (2016) 10-21.
- [39] P. Castets, S. Lin, N. Rion, S. Di Fulvio, K. Romanino, M. Guridi, S. Frank, L.A. Tintignac, M. Sinnreich, M.A. Ruegg, Sustained activation of mTORC1 in skeletal muscle inhibits constitutive and starvation-induced autophagy and causes a severe, late-onset myopathy, *Cell Metab* 17(5) (2013) 731-44.
- [40] J.M. Dickinson, C.S. Fry, M.J. Drummond, D.M. Gundermann, D.K. Walker, E.L. Glynn, K.L. Timmerman, S. Dhanani, E. Volpi, B.B. Rasmussen, Mammalian target of rapamycin complex 1 activation is required for the stimulation of human skeletal muscle protein synthesis by essential amino acids, *J Nutr* 141(5) (2011) 856-62.
- [41] N. Kubica, S.R. Kimball, L.S. Jefferson, P.A. Farrell, Alterations in the expression of mRNAs and proteins that code for species relevant to eIF2B activity after an acute bout of resistance exercise, *J Appl Physiol* (1985) 96(2) (2004) 679-87.
- [42] M.J. Drummond, C.S. Fry, E.L. Glynn, H.C. Dreyer, S. Dhanani, K.L. Timmerman, E. Volpi, B.B. Rasmussen, Rapamycin administration in humans blocks the contraction-induced increase in skeletal muscle protein synthesis, *J Physiol* 587(Pt 7) (2009) 1535-46.
- [43] J.M. Dickinson, M.J. Drummond, C.S. Fry, D.M. Gundermann, D.K. Walker, K.L. Timmerman, E. Volpi, B.B. Rasmussen, Rapamycin does not affect post-absorptive protein metabolism in human skeletal muscle, *Metabolism* 62(1) (2013) 144-51.
- [44] T. Phillips, C. Leeuwenburgh, Muscle fiber specific apoptosis and TNF-alpha signaling in sarcopenia are attenuated by life-long calorie restriction, *FASEB J* 19(6) (2005) 668-70.
- [45] C. Handschin, Caloric restriction and exercise "mimetics": Ready for prime time?, *Pharmacological research* 103 (2016) 158-66.
- [46] J.F. Gill, G. Santos, S. Schnyder, C. Handschin, PGC-1alpha affects aging-related changes in muscle and motor function by modulating specific exercise-mediated changes in old mice, *Aging Cell* 17(1) (2018).
- [47] I. Beyer, T. Mets, I. Bautmans, Chronic low-grade inflammation and age-related sarcopenia, *Curr Opin Clin Nutr Metab Care* 15(1) (2012) 12-22.
- [48] C. Handschin, B.M. Spiegelman, The role of exercise and PGC1alpha in inflammation and chronic disease, *Nature* 454(7203) (2008) 463-9.
- [49] R. Furrer, C. Handschin, Muscle Wasting Diseases: Novel Targets and Treatments, *Annu Rev Pharmacol Toxicol* (2018).
- [50] G. Bano, C. Trevisan, S. Carraro, M. Solmi, C. Luchini, B. Stubbs, E. Manzato, G. Sergi, N. Veronese, Inflammation and sarcopenia: A systematic review and meta-analysis, *Maturitas* 96 (2017) 10-15.
- [51] K.S. Krabbe, M. Pedersen, H. Bruunsgaard, Inflammatory mediators in the elderly, *Exp Gerontol* 39(5) (2004) 687-99.
- [52] B. Wahlin-Larsson, D.J. Wilkinson, E. Strandberg, A. Hosford-Donovan, P.J. Atherton, F. Kadi, Mechanistic Links Underlying the Impact of C-Reactive Protein on Muscle Mass in Elderly, *Cell Physiol Biochem* 44(1) (2017) 267-278.
- [53] C. Franceschi, P. Garagnani, P. Parini, C. Giuliani, A. Santoro, Inflammaging: a new immune-metabolic viewpoint for age-related diseases, *Nat Rev Endocrinol* 14(10) (2018) 576-590.

[54] I. Rieu, H. Magne, I. Savary-Auzeloux, J. Averous, C. Bos, M.A. Peyron, L. Combaret, D. Dardevet, Reduction of low grade inflammation restores blunting of postprandial muscle anabolism and limits sarcopenia in old rats, *J Physiol* 587(Pt 22) (2009) 5483-92.

[55] M. Machida, T. Takemasa, Ibuprofen administration during endurance training cancels running-distance-dependent adaptations of skeletal muscle in mice, *J Physiol Pharmacol* 61(5) (2010) 559-63.

[56] R.T. Enos, J.M. Davis, J.L. McClellan, E.A. Murphy, Indomethacin in combination with exercise leads to muscle and brain inflammation in mice, *J Interferon Cytokine Res* 33(8) (2013) 446-51.

[57] M. Lilja, M. Mandic, W. Apro, M. Melin, K. Olsson, S. Rosenborg, T. Gustafsson, T.R. Lundberg, High doses of anti-inflammatory drugs compromise muscle strength and hypertrophic adaptations to resistance training in young adults, *Acta Physiol (Oxf)* 222(2) (2018).

[58] K. Dideriksen, A.P. Boesen, J.F. Kristiansen, S.P. Magnusson, P. Schjerling, L. Holm, M. Kjaer, Skeletal muscle adaptation to immobilization and subsequent retraining in elderly men: No effect of anti-inflammatory medication, *Exp Gerontol* 82 (2016) 8-18.

[59] K. Dideriksen, S. Reitelseder, N.M. Malmgaard-Clausen, R. Bechshoeft, R.K. Petersen, U.R. Mikkelsen, L. Holm, No effect of anti-inflammatory medication on postprandial and postexercise muscle protein synthesis in elderly men with slightly elevated systemic inflammation, *Exp Gerontol* 83 (2016) 120-9.

[60] T.A. Trappe, C.C. Carroll, J.M. Dickinson, J.K. LeMoine, J.M. Haus, B.E. Sullivan, J.D. Lee, B. Jemio, E.M. Weinheimer, C.J. Hollon, Influence of acetaminophen and ibuprofen on skeletal muscle adaptations to resistance exercise in older adults, *Am J Physiol Regul Integr Comp Physiol* 300(3) (2011) R655-62.

[61] T.A. Trappe, R.A. Standley, B. Jemio, C.C. Carroll, S.W. Trappe, Prostaglandin and myokine involvement in the cyclooxygenase-inhibiting drug enhancement of skeletal muscle adaptations to resistance exercise in older adults, *Am J Physiol Regul Integr Comp Physiol* 304(3) (2013) R198-205.

[62] T.W. Buford, T.M. Manini, F.C. Hsu, M. Cesari, S.D. Anton, S. Nayfield, R.S. Stafford, T.S. Church, M. Pahor, C.S. Carter, Angiotensin-converting enzyme inhibitor use by older adults is associated with greater functional responses to exercise, *J Am Geriatr Soc* 60(7) (2012) 1244-52.

[63] M. Alturki, I. Beyer, T. Mets, I. Bautmans, Impact of drugs with anti-inflammatory effects on skeletal muscle and inflammation: A systematic literature review, *Exp Gerontol* 114 (2018) 33-49.

[64] Z. Puthucherry, J.R. Skipworth, J. Rawal, M. Loosemore, K. Van Someren, H.E. Montgomery, The ACE gene and human performance: 12 years on, *Sports Med* 41(6) (2011) 433-48.

[65] M. Brink, S.R. Price, J. Chrast, J.L. Bailey, A. Anwar, W.E. Mitch, P. Delafontaine, Angiotensin II induces skeletal muscle wasting through enhanced protein degradation and down-regulates autocrine insulin-like growth factor I, *Endocrinology* 142(4) (2001) 1489-96.

[66] Y.H. Song, Y. Li, J. Du, W.E. Mitch, N. Rosenthal, P. Delafontaine, Muscle-specific expression of IGF-1 blocks angiotensin II-induced skeletal muscle wasting, *J Clin Invest* 115(2) (2005) 451-8.

[67] L. Sartiani, V. Spinelli, A. Laurino, S. Blescia, L. Raimondi, E. Cerbai, A. Mugelli, Pharmacological perspectives in sarcopenia: a potential role for renin-angiotensin system blockers?, *Clin Cases Miner Bone Metab* 12(2) (2015) 135-8.

[68] G. Onder, B.W. Penninx, R. Balkrishnan, L.P. Fried, P.H. Chaves, J. Williamson, C. Carter, M. Di Bari, J.M. Guralnik, M. Pahor, Relation between use of angiotensin-converting enzyme inhibitors and muscle strength and physical function in older women: an observational study, *Lancet* 359(9310) (2002) 926-30.

[69] D. Sumukadas, M.D. Witham, A.D. Struthers, M.E. McMurdo, Effect of perindopril on physical function in elderly people with functional impairment: a randomized controlled trial, *CMAJ* 177(8) (2007) 867-74.

[70] M. Cesari, S.B. Kritchevsky, H.H. Atkinson, B.W. Penninx, M. Di Bari, R.P. Tracy, M. Pahor, Angiotensin-converting enzyme inhibition and novel cardiovascular risk biomarkers: results from the Trial of Angiotensin Converting Enzyme Inhibition and Novel Cardiovascular Risk Factors (TRAIN) study, *Am Heart J* 157(2) (2009) 334 e1-8.

[71] M. Cesari, C. Pedone, R.A. Incalzi, M. Pahor, ACE-inhibition and physical function: results from the Trial of Angiotensin-Converting Enzyme Inhibition and Novel Cardiovascular Risk Factors (TRAIN) study, *J Am Med Dir Assoc* 11(1) (2010) 26-32.

- [72] T.N. Burks, E. Andres-Mateos, R. Marx, R. Mejias, C. Van Erp, J.L. Simmers, J.D. Walston, C.W. Ward, R.D. Cohn, Losartan restores skeletal muscle remodeling and protects against disuse atrophy in sarcopenia, *Sci Transl Med* 3(82) (2011) 82ra37.
- [73] C.H. Lin, H. Yang, Q.L. Xue, Y.F. Chuang, C.N. Roy, P. Abadir, J.D. Walston, Losartan improves measures of activity, inflammation, and oxidative stress in older mice, *Exp Gerontol* 58 (2014) 174-8.
- [74] M.A. Egerman, S.M. Cadena, J.A. Gilbert, A. Meyer, H.N. Nelson, S.E. Swalley, C. Mallozzi, C. Jacobi, L.L. Jennings, I. Clay, G. Laurent, S. Ma, S. Brachar, E. Lach-Trifilieff, T. Shavlakadze, A.U. Trendelenburg, A.S. Brack, D.J. Glass, GDF11 Increases with Age and Inhibits Skeletal Muscle Regeneration, *Cell Metab* 22(1) (2015) 164-74.
- [75] M.J. Schafer, E.J. Atkinson, P.M. Vanderboom, B. Kotajarvi, T.A. White, M.M. Moore, C.J. Bruce, K.L. Greason, R.M. Suri, S. Khosla, J.D. Miller, H.R. Bergen, 3rd, N.K. LeBrasseur, Quantification of GDF11 and Myostatin in Human Aging and Cardiovascular Disease, *Cell Metab* 23(6) (2016) 1207-1215.
- [76] V. Siriett, L. Platt, M.S. Salerno, N. Ling, R. Kambadur, M. Sharma, Prolonged absence of myostatin reduces sarcopenia, *J Cell Physiol* 209(3) (2006) 866-73.
- [77] M.R. Morissette, J.C. Stricker, M.A. Rosenberg, C. Buranasombati, E.B. Levitan, M.A. Mittleman, A. Rosenzweig, Effects of myostatin deletion in aging mice, *Aging Cell* 8(5) (2009) 573-83.
- [78] C. Becker, S.R. Lord, S.A. Studenski, S.J. Warden, R.A. Fielding, C.P. Recknor, M.C. Hochberg, S.L. Ferrari, H. Blain, E.F. Binder, Y. Rolland, S. Poiraudeau, C.T. Benson, S.L. Myers, L. Hu, Q.I. Ahmad, K.R. Pacuch, E.V. Gomez, O. Benichou, S. Group, Myostatin antibody (LY2495655) in older weak fallers: a proof-of-concept, randomised, phase 2 trial, *Lancet Diabetes Endocrinol* 3(12) (2015) 948-57.
- [79] N. Ebner, S. von Haehling, Unlocking the wasting enigma: Highlights from the 8th Cachexia Conference, *J Cachexia Sarcopenia Muscle* 7(1) (2016) 90-4.
- [80] E. Lach-Trifilieff, G.C. Minetti, K. Sheppard, C. Ibebunjo, J.N. Feige, S. Hartmann, S. Brachar, H. Rivet, C. Koelbing, F. Morvan, S. Hatakeyama, D.J. Glass, An antibody blocking activin type II receptors induces strong skeletal muscle hypertrophy and protects from atrophy, *Mol Cell Biol* 34(4) (2014) 606-18.
- [81] F.C. Wu, A. Tajar, S.R. Pye, A.J. Silman, J.D. Finn, T.W. O'Neill, G. Bartfai, F. Casanueva, G. Forti, A. Giwercman, I.T. Huhtaniemi, K. Kula, M. Punab, S. Boonen, D. Vanderschueren, G. European Male Aging Study, Hypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: the European Male Aging Study, *J Clin Endocrinol Metab* 93(7) (2008) 2737-45.
- [82] S.M. Harman, E.J. Metter, J.D. Tobin, J. Pearson, M.R. Blackman, A. Baltimore Longitudinal Study of, Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging, *J Clin Endocrinol Metab* 86(2) (2001) 724-31.
- [83] T.G. Travison, H.W. Vesper, E. Orwoll, F. Wu, J.M. Kaufman, Y. Wang, B. Lapauw, T. Fiers, A.M. Matsumoto, S. Bhasin, Harmonized Reference Ranges for Circulating Testosterone Levels in Men of Four Cohort Studies in the United States and Europe, *J Clin Endocrinol Metab* 102(4) (2017) 1161-1173.
- [84] H.A. Feldman, C. Longcope, C.A. Derby, C.B. Johannes, A.B. Araujo, A.D. Coviello, W.J. Bremner, J.B. McKinlay, Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study, *J Clin Endocrinol Metab* 87(2) (2002) 589-98.
- [85] I. Sinha-Hikim, J. Artaza, L. Woodhouse, N. Gonzalez-Cadavid, A.B. Singh, M.I. Lee, T.W. Storer, R. Casaburi, R. Shen, S. Bhasin, Testosterone-induced increase in muscle size in healthy young men is associated with muscle fiber hypertrophy, *Am J Physiol Endocrinol Metab* 283(1) (2002) E154-64.
- [86] R.A. Atkinson, U. Srinivas-Shankar, S.A. Roberts, M.J. Connolly, J.E. Adams, J.A. Oldham, F.C. Wu, O.R. Seynnes, C.E. Stewart, C.N. Maganaris, M.V. Narici, Effects of testosterone on skeletal muscle architecture in intermediate-frail and frail elderly men, *J Gerontol A Biol Sci Med Sci* 65(11) (2010) 1215-9.
- [87] J.E. Morley, H.M. Perry, 3rd, Androgens and women at the menopause and beyond, *J Gerontol A Biol Sci Med Sci* 58(5) (2003) M409-16.

628 [88] M.L. Rossetti, J.L. Steiner, B.S. Gordon, Androgen-mediated regulation of skeletal muscle protein
629 balance, *Mol Cell Endocrinol* 447 (2017) 35-44.

630 [89] W.K. Neto, E.F. Gama, L.Y. Rocha, C.C. Ramos, W. Taets, K.B. Scapini, J.B. Ferreira, B. Rodrigues,
631 E. Caperuto, Effects of testosterone on lean mass gain in elderly men: systematic review with meta-
632 analysis of controlled and randomized studies, *Age (Dordr)* 37(1) (2015) 9742.

633 [90] U. Srinivas-Shankar, S.A. Roberts, M.J. Connolly, M.D. O'Connell, J.E. Adams, J.A. Oldham, F.C.
634 Wu, Effects of testosterone on muscle strength, physical function, body composition, and quality of
635 life in intermediate-frail and frail elderly men: a randomized, double-blind, placebo-controlled study,
636 *J Clin Endocrinol Metab* 95(2) (2010) 639-50.

637 [91] O.J. Ponce, G. Spencer-Bonilla, N. Alvarez-Villalobos, V. Serrano, N. Singh-Ospina, R. Rodriguez-
638 Gutierrez, A. Salcido-Montenegro, R. Benkhadra, L.J. Prokop, S. Bhasin, J.P. Brito, The efficacy and
639 adverse events of testosterone replacement therapy in hypogonadal men: A systematic review and
640 meta-analysis of randomized, placebo-controlled trials, *J Clin Endocrinol Metab* (2018).

641 [92] P.J. Snyder, S. Bhasin, G.R. Cunningham, A.M. Matsumoto, A.J. Stephens-Shields, J.A. Cauley,
642 T.M. Gill, E. Barrett-Connor, R.S. Swerdloff, C. Wang, K.E. Ensrud, C.E. Lewis, J.T. Farrar, D. Cella, R.C.
643 Rosen, M. Pahor, J.P. Crandall, M.E. Molitch, D. Cifelli, D. Dougar, L. Fluharty, S.M. Resnick, T.W.
644 Storer, S. Anton, S. Basaria, S.J. Diem, X. Hou, E.R. Mohler, 3rd, J.K. Parsons, N.K. Wenger, B. Zeldow,
645 J.R. Landis, S.S. Ellenberg, I. Testosterone Trials, Effects of Testosterone Treatment in Older Men, *N*
646 *Engl J Med* 374(7) (2016) 611-24.

647 [93] S. Bhasin, S.S. Ellenberg, T.W. Storer, S. Basaria, M. Pahor, A.J. Stephens-Shields, J.A. Cauley, K.E.
648 Ensrud, J.T. Farrar, D. Cella, A.M. Matsumoto, G.R. Cunningham, R.S. Swerdloff, C. Wang, C.E. Lewis,
649 M.E. Molitch, E. Barrett-Connor, J.P. Crandall, X. Hou, P. Preston, D. Cifelli, P.J. Snyder, T.M. Gill,
650 Effect of testosterone replacement on measures of mobility in older men with mobility limitation and
651 low testosterone concentrations: secondary analyses of the Testosterone Trials, *Lancet Diabetes*
652 *Endocrinol* 6(11) (2018) 879-890.

653 [94] J.T. Dalton, K.G. Barnette, C.E. Bohl, M.L. Hancock, D. Rodriguez, S.T. Dodson, R.A. Morton, M.S.
654 Steiner, The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass
655 and physical function in healthy elderly men and postmenopausal women: results of a double-blind,
656 placebo-controlled phase II trial, *J Cachexia Sarcopenia Muscle* 2(3) (2011) 153-161.

657 [95] D.A. Papanicolaou, S.N. Ather, H. Zhu, Y. Zhou, J. Lutkiewicz, B.B. Scott, J. Chandler, A phase IIA
658 randomized, placebo-controlled clinical trial to study the efficacy and safety of the selective
659 androgen receptor modulator (SARM), MK-0773 in female participants with sarcopenia, *J Nutr Health*
660 *Aging* 17(6) (2013) 533-43.

661 [96] M.A. Egerman, D.J. Glass, Signaling pathways controlling skeletal muscle mass, *Crit Rev Biochem*
662 *Mol Biol* 49(1) (2014) 59-68.

663 [97] H. Kim, E. Barton, N. Muja, S. Yakar, P. Pennisi, D. Leroith, Intact insulin and insulin-like growth
664 factor-I receptor signaling is required for growth hormone effects on skeletal muscle growth and
665 function in vivo, *Endocrinology* 146(4) (2005) 1772-9.

666 [98] R.K. Junnila, E.O. List, D.E. Berryman, J.W. Murrey, J.J. Kopchick, The GH/IGF-1 axis in ageing and
667 longevity, *Nat Rev Endocrinol* 9(6) (2013) 366-376.

668 [99] D. Rudman, A.G. Feller, H.S. Nagraj, G.A. Gergans, P.Y. Lalitha, A.F. Goldberg, R.A. Schlenker, L.
669 Cohn, I.W. Rudman, D.E. Mattson, Effects of human growth hormone in men over 60 years old, *N*
670 *Engl J Med* 323(1) (1990) 1-6.

671 [100] A.P. Boesen, K. Dideriksen, C. Couppe, S.P. Magnusson, P. Schjerling, M. Boesen, P. Aagaard, M.
672 Kjaer, H. Langberg, Effect of growth hormone on aging connective tissue in muscle and tendon: gene
673 expression, morphology, and function following immobilization and rehabilitation, *J Appl Physiol*
674 (1985) 116(2) (2014) 192-203.

675 [101] G.E. Butterfield, J. Thompson, M.J. Rennie, R. Marcus, R.L. Hintz, A.R. Hoffman, Effect of rhGH
676 and rhIGF-I treatment on protein utilization in elderly women, *Am J Physiol* 272(1 Pt 1) (1997) E94-9.

677 [102] A. Philippou, E.R. Barton, Optimizing IGF-I for skeletal muscle therapeutics, *Growth hormone &*
678 *IGF research : official journal of the Growth Hormone Research Society and the International IGF*
679 *Research Society* 24(5) (2014) 157-63.



- [103] H. Liu, D.M. Bravata, I. Olkin, S. Nayak, B. Roberts, A.M. Garber, A.R. Hoffman, Systematic review: the safety and efficacy of growth hormone in the healthy elderly, *Ann Intern Med* 146(2) (2007) 104-15.
- [104] M.F. Holick, Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease, *Am J Clin Nutr* 80(6 Suppl) (2004) 1678S-88S.
- [105] W.G. Tsiaras, M.A. Weinstock, Factors influencing vitamin D status, *Acta Derm Venereol* 91(2) (2011) 115-24.
- [106] B. Kupr, S. Schnyder, C. Handschin, Role of Nuclear Receptors in Exercise-Induced Muscle Adaptations, *Cold Spring Harb Perspect Med* 7(6) (2017).
- [107] Y.C. Li, A.E. Pirro, M. Amling, G. Delling, R. Baron, R. Bronson, M.B. Demay, Targeted ablation of the vitamin D receptor: an animal model of vitamin D-dependent rickets type II with alopecia, *Proc Natl Acad Sci U S A* 94(18) (1997) 9831-5.
- [108] A. Wagatsuma, K. Sakuma, Vitamin D signaling in myogenesis: potential for treatment of sarcopenia, *Biomed Res Int* 2014 (2014) 121254.
- [109] K.A. Stockton, K. Mengersen, J.D. Paratz, D. Kandiah, K.L. Bennell, Effect of vitamin D supplementation on muscle strength: a systematic review and meta-analysis, *Osteoporos Int* 22(3) (2011) 859-71.
- [110] H.A. Bischoff-Ferrari, M. Borchers, F. Gudat, U. Durmuller, H.B. Stahelin, W. Dick, Vitamin D receptor expression in human muscle tissue decreases with age, *J Bone Miner Res* 19(2) (2004) 265-269.
- [111] Z. Xia, Q. Man, L. Li, P. Song, S. Jia, S. Song, L. Meng, J. Zhang, Vitamin D receptor gene polymorphisms modify the association of serum 25-hydroxyvitamin D levels with handgrip strength in the elderly in Northern China, *Nutrition* 57 (2018) 202-207.
- [112] S. Verlaan, A.B. Maier, J.M. Bauer, I. Bautmans, K. Brandt, L.M. Donini, M. Maggio, M.E.T. McMurdo, T. Mets, C. Seal, S.L.J. Wijers, C. Sieber, Y. Boirie, T. Cederholm, Sufficient levels of 25-hydroxyvitamin D and protein intake required to increase muscle mass in sarcopenic older adults - The PROVIDE study, *Clin Nutr* 37(2) (2018) 551-557.
- [113] J.C. Fuller, Jr., S. Baier, P. Flakoll, S.L. Nissen, N.N. Abumrad, J.A. Rathmacher, Vitamin D status affects strength gains in older adults supplemented with a combination of beta-hydroxy-beta-methylbutyrate, arginine, and lysine: a cohort study, *JPEN J Parenter Enteral Nutr* 35(6) (2011) 757-62.
- [114] S.W. Muir, M. Montero-Odasso, Effect of vitamin D supplementation on muscle strength, gait and balance in older adults: a systematic review and meta-analysis, *J Am Geriatr Soc* 59(12) (2011) 2291-300.
- [115] L. Ceglia, S. Niramitmahapanya, M. da Silva Morais, D.A. Rivas, S.S. Harris, H. Bischoff-Ferrari, R.A. Fielding, B. Dawson-Hughes, A randomized study on the effect of vitamin D(3) supplementation on skeletal muscle morphology and vitamin D receptor concentration in older women, *J Clin Endocrinol Metab* 98(12) (2013) E1927-35.
- [116] A.E. Antoniak, C.A. Greig, The effect of combined resistance exercise training and vitamin D3 supplementation on musculoskeletal health and function in older adults: a systematic review and meta-analysis, *BMJ Open* 7(7) (2017) e014619.
- [117] C. Beaudart, F. Buckinx, V. Rabenda, S. Gillain, E. Cavalier, J. Slomian, J. Petermans, J.Y. Reginster, O. Bruyere, The effects of vitamin D on skeletal muscle strength, muscle mass, and muscle power: a systematic review and meta-analysis of randomized controlled trials, *J Clin Endocrinol Metab* 99(11) (2014) 4336-45.
- [118] O. Bruyere, E. Cavalier, J.C. Souberbielle, H.A. Bischoff-Ferrari, C. Beaudart, F. Buckinx, J.Y. Reginster, R. Rizzoli, Effects of vitamin D in the elderly population: current status and perspectives, *Arch Public Health* 72(1) (2014) 32.
- [119] M.J. Bolland, A. Grey, A. Avenell, Effects of vitamin D supplementation on musculoskeletal health: a systematic review, meta-analysis, and trial sequential analysis, *Lancet Diabetes Endocrinol* 6(11) (2018) 847-858.
- [120] M. Kojima, H. Hosoda, Y. Date, M. Nakazato, H. Matsuo, K. Kangawa, Ghrelin is a growth-hormone-releasing acylated peptide from stomach, *Nature* 402(6762) (1999) 656-60.

- [121] G. Collden, M.H. Tschop, T.D. Muller, Therapeutic Potential of Targeting the Ghrelin Pathway, *Int J Mol Sci* 18(4) (2017).
- [122] H.K. White, C.D. Petrie, W. Landschulz, D. MacLean, A. Taylor, K. Lyles, J.Y. Wei, A.R. Hoffman, R. Salvatori, M.P. Ettinger, M.C. Morey, M.R. Blackman, G.R. Merriam, G. Capromorelin Study, Effects of an oral growth hormone secretagogue in older adults, *J Clin Endocrinol Metab* 94(4) (2009) 1198-206.
- [123] R. Nass, S.S. Pezzoli, M.C. Oliveri, J.T. Patrie, F.E. Harrell, Jr., J.L. Clasey, S.B. Heymsfield, M.A. Bach, M.L. Vance, M.O. Thorner, Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial, *Ann Intern Med* 149(9) (2008) 601-11.
- [124] A. Adunsky, J. Chandler, N. Heyden, J. Lutkiewicz, B.B. Scott, Y. Berd, N. Liu, D.A. Papanicolaou, MK-0677 (ibutamoren mesylate) for the treatment of patients recovering from hip fracture: a multicenter, randomized, placebo-controlled phase IIb study, *Arch Gerontol Geriatr* 53(2) (2011) 183-9.
- [125] M. Blagosklonny, Disease or not, aging is easily treatable, *Aging (Albany NY)* 10(11) (2018) 3067-78.
- [126] M. Weihrauch, C. Handschin, Pharmacological targeting of exercise adaptations in skeletal muscle: Benefits and pitfalls, *Biochem Pharmacol* 147 (2018) 211-220.
- [127] B.K. Pedersen, B. Saltin, Exercise as medicine - evidence for prescribing exercise as therapy in 26 different chronic diseases, *Scand J Med Sci Sports* 25 Suppl 3 (2015) 1-72.
- [128] F.W. Booth, C.K. Roberts, J.P. Thyfault, G.N. Ruegsegger, R.G. Toedebusch, Role of Inactivity in Chronic Diseases: Evolutionary Insight and Pathophysiological Mechanisms, *Physiol Rev* 97(4) (2017) 1351-1402.

Figure Legend




Figure 1. Schematic overview on the nutritional and pharmacological targets and the related signaling pathways to control muscle protein biosynthesis (marked in light blue) and breakdown (marked in orange) in sarcopenia. Abbreviations: ACE, angiotensin-converting enzyme; ActRIIB, activin type IIB receptor; ALK4/5, activin receptor-like kinase 4 or 5; AMPK, AMP-dependent protein kinase, Ang I/II, angiotensin I or II; AT1R, angiotensin receptor type 1; AR, androgen receptor; COX-1/2, cyclooxygenase 1 or 2; FoxO, forkhead box O; GH, growth hormone; IGF-1, insulin-like growth factor 1; Insulin-R, insulin receptor; IGF-1R, IGF-1 receptor; mTORC1, mammalian target of rapamycin complex 1; NF- κ B, nuclear factor κ B; n-3 PUFAs, omega-3 poly unsaturated fatty acids; PI3K, phosphoinositide 3-kinase; PKB, protein kinase B; SARMs, selective androgen receptor modulators; S6K1, ribosomal protein S6 kinase 1; 4E-BP1, eukaryotic translation initiation factor 4E-binding protein 1.

Caloric restriction




UVB

Dietary protein




Drugs



Inflammation

n-3 PUFAs



Inflammation



Exercise



